Chott A, Haedicke W, Mosberger I, Födinger M, Winkler K, Mannhalter C, Müller-Hermelink H K
Department of Clinical Pathology, University of Vienna, Austria.
Am J Pathol. 1998 Nov;153(5):1483-90. doi: 10.1016/S0002-9440(10)65736-7.
The expression of the natural killer (NK) cell marker CD56 has been reported to occur in NK cell lymphomas/leukemias and a small group of peripheral T-cell lymphomas but has not been studied extensively in primary intestinal non-B-cell lymphomas. Normal human jejunal intraepithelial lymphocytes (IELs) are mainly T-cell receptor (TCR)-alphabeta+CD3+CD8+CD5low and include an approximately 15% fraction of CD56+ cells that could be the cells of origin for CD56+ intestinal T-cell lymphoma (ITL). To test this hypothesis, 70 cases diagnosed as ITL were immunophenotyped, and 15 CD56+ cases (21%) were identified. The majority of the CD56+ lymphomas was of monomorphic small to medium-sized histology, shared the common phenotype betaF1+/-CD3epsilon/cyt+CD8+CD4-CD5-CD57-TIA-1+ and had clonally rearranged TCR gamma-chain genes. In contrast, the CD56- lymphomas were mainly composed of pleomorphic medium and large cells or had a morphology most consistent with anaplastic large-cell lymphoma and were mostly CD8-. These findings suggest that the majority of CD56+ intestinal lymphomas are morphologically and phenotypically distinct T-cell lymphomas most likely derived from activated cytotoxic CD56+CD8+ IELs. Some overlapping histological and clinical features between CD56+ and CD56- ITLs indicate that the former belong to the clinicopathological entity of ITL. The consistent expression of cytotoxic-granule-associated proteins introduces ITL (both CD56+ and CD56-) into the growing family of usually aggressive extranodal lymphomas of cytotoxic T-cell and NK-cell derivation. In contrast to putative NK-cell lymphoma of the sinonasal region, intestinal NK-cell lymphoma seems to be very rare.
据报道,自然杀伤(NK)细胞标志物CD56在NK细胞淋巴瘤/白血病及一小部分外周T细胞淋巴瘤中表达,但在原发性肠道非B细胞淋巴瘤中尚未得到广泛研究。正常人类空肠上皮内淋巴细胞(IEL)主要为T细胞受体(TCR)αβ⁺CD3⁺CD8⁺CD5低表达,其中约15%为CD56⁺细胞,可能是CD56⁺肠道T细胞淋巴瘤(ITL)的起源细胞。为验证这一假说,对70例诊断为ITL的病例进行了免疫表型分析,共鉴定出15例CD56⁺病例(21%)。大多数CD56⁺淋巴瘤为单形性小至中等大小组织学类型,具有共同表型βF1⁺/⁻CD3ε/胞质⁺CD8⁺CD4⁻CD5⁻CD57⁻TIA-1⁺,且TCRγ链基因发生克隆性重排。相比之下,CD56⁻淋巴瘤主要由多形性中、大细胞组成,或形态与间变性大细胞淋巴瘤最为一致,且大多为CD8⁻。这些发现表明,大多数CD56⁺肠道淋巴瘤是形态和表型上不同的T细胞淋巴瘤,很可能起源于活化的细胞毒性CD56⁺CD8⁺IEL。CD56⁺和CD56⁻ITL之间一些重叠的组织学和临床特征表明,前者属于ITL的临床病理实体。细胞毒性颗粒相关蛋白的一致表达将ITL(CD56⁺和CD56⁻)纳入了通常侵袭性较强的细胞毒性T细胞和NK细胞来源的结外淋巴瘤这一不断扩大的家族。与鼻窦区假定的NK细胞淋巴瘤不同,肠道NK细胞淋巴瘤似乎非常罕见。